Genetic Testing for Mesothelioma: Types, Benefits, and What Results Mean

Key Facts

BAP1 mutations occur in 60% of mesotheliomas and indicate better prognosis

CDKN2A deletions found in 70% of cases help confirm mesothelioma diagnosis

Genetic testing can identify targetable mutations for clinical trials

Germline BAP1 testing can reveal hereditary cancer risk for family members

Why Genetic Testing Matters for Mesothelioma

Genetic testing has transformed mesothelioma care. By analyzing the DNA of tumor cells, doctors can:

Confirm diagnosis: Certain genetic changes help distinguish mesothelioma from other cancers
Predict prognosis: Some mutations indicate better or worse outcomes
Guide treatment: Identify patients who may respond to specific therapies
Determine trial eligibility: Many clinical trials require specific genetic profiles
Assess hereditary risk: Identify families who may benefit from cancer surveillance

Personalized Medicine

Genetic testing enables precision medicine, where treatment is tailored to the specific mutations in your tumor rather than a one-size-fits-all approach.

Types of Genetic Testing

Tumor Testing (Somatic Testing)

This tests the DNA of cancer cells from a biopsy or surgical specimen. The mutations found are specific to the tumor and are not inherited.

Common tests:

Next-generation sequencing (NGS)
Fluorescence in situ hybridization (FISH)
Immunohistochemistry (IHC)

Germline Testing

This tests DNA from normal cells (usually blood or saliva) to look for inherited mutations that increase cancer risk.

When recommended:

Family history of mesothelioma
Early age at diagnosis (under 50)
Multiple cancers in patient or family
BAP1 loss found in tumor

Both Tests May Be Needed

If your tumor shows BAP1 loss, germline testing can determine if the mutation was inherited. This has important implications for family members.

Key Genes Tested in Mesothelioma

BAP1 (BRCA1-Associated Protein 1)

Frequency: Mutated in approximately 60% of mesotheliomas

What it does: BAP1 is a tumor suppressor gene that helps repair DNA damage. When BAP1 is lost, cells cannot properly fix DNA errors.

Testing methods:

Method	What It Shows	Turnaround
IHC (immunohistochemistry)	Protein expression	2-3 days
FISH	Gene deletion	3-5 days
NGS	Specific mutations	2-3 weeks

Why it matters:

Diagnosis: BAP1 loss supports mesothelioma diagnosis
Prognosis: Paradoxically, BAP1-deficient tumors often have better survival
Treatment: May qualify for EZH2 inhibitor trials
Hereditary risk: 20-25% of BAP1 mutations are inherited

CDKN2A (p16)

Frequency: Deleted in up to 70% of mesotheliomas

What it does: CDKN2A produces proteins (p16 and p14ARF) that control cell division. Deletion removes this brake on cell growth.

Testing method: FISH is the gold standard for detecting CDKN2A deletion

Why it matters:

Diagnosis: CDKN2A deletion is highly specific for malignant mesothelioma (helps distinguish from benign conditions)
Prognosis: Homozygous deletion associated with worse outcomes
Treatment: CDK4/6 inhibitors may benefit these patients

Diagnostic Distinction

CDKN2A deletion testing is one of the most valuable tests for distinguishing malignant mesothelioma from reactive mesothelial proliferation (a benign condition that can look similar).

NF2 (Neurofibromin 2)

Frequency: Mutated in approximately 40% of mesotheliomas

What it does: NF2 regulates the Hippo signaling pathway. When NF2 is lost, cells receive constant “grow” signals.

Why it matters:

Treatment: TEAD inhibitor trials targeting Hippo pathway dysfunction
Clinical trials: Specific eligibility for NF2-mutated tumor trials (VT3989, IK-930)

Other Relevant Genes

Gene	Frequency	Clinical Relevance
SETD2	10-15%	DNA repair defects
TP53	5-10%	General tumor suppressor
LATS2	10%	Hippo pathway component
PBRM1	5-10%	Chromatin remodeling

Testing Methods Explained

Next-Generation Sequencing (NGS)

NGS analyzes hundreds of genes simultaneously from a single sample.

Advantages:

Comprehensive: Tests many genes at once
Identifies novel mutations
Detects mutation type and variant

Considerations:

Requires adequate tumor tissue
Takes 2-3 weeks for results
More expensive than single-gene tests

When to use: When comprehensive profiling is needed, especially to identify trial eligibility

FISH (Fluorescence In Situ Hybridization)

FISH uses fluorescent probes to detect specific genetic changes.

Best for:

CDKN2A deletion detection
Quick turnaround (3-5 days)
Can be done on small samples

Limitations:

Tests only specific targets
Does not identify point mutations

Immunohistochemistry (IHC)

IHC tests for protein expression using antibodies.

Best for:

BAP1 protein loss
Same-day or next-day results
Very small tissue samples

Limitations:

Indirect: Shows protein loss, not the mutation itself
May miss some mutations

Commercial Testing Laboratories

Several commercial laboratories offer comprehensive mesothelioma testing:

Laboratory	Test Name	Genes Covered
Foundation Medicine	FoundationOne CDx	324 genes
Tempus	xT	648 genes
Caris Life Sciences	MI Profile	592 genes
Guardant Health	Guardant360	83 genes (liquid biopsy)

Most major cancer centers also have in-house molecular pathology labs.

Insurance Coverage

Comprehensive genomic testing is increasingly covered by insurance, especially for patients with advanced cancer or when results may guide treatment decisions.

Understanding Your Results

BAP1 Testing Results

“BAP1 loss” or “BAP1 absent” (by IHC):

Tumor cells have lost BAP1 protein expression
Supports mesothelioma diagnosis
May indicate better prognosis
Consider germline testing

“BAP1 retained” or “BAP1 present”:

BAP1 is functioning normally
Does not rule out mesothelioma
Other mutations may be driving the cancer

CDKN2A Testing Results

“Homozygous deletion”:

Both copies of the gene are lost
Strongly supports malignant mesothelioma diagnosis
Associated with more aggressive disease

“Heterozygous deletion” or “No deletion”:

One or no copies lost
Does not rule out mesothelioma
May indicate less aggressive biology

NGS Report Interpretation

NGS reports typically include:

Section	What It Shows
Pathogenic mutations	Definitely disease-causing changes
Likely pathogenic	Probably disease-causing
Variants of uncertain significance (VUS)	Unknown importance
Tumor mutational burden (TMB)	Total number of mutations
Microsatellite instability (MSI)	DNA repair status

How Results Guide Treatment

Clinical Trial Eligibility

Many clinical trials require specific genetic profiles:

Mutation	Relevant Trials
BAP1 loss	EZH2 inhibitor trials (tazemetostat)
NF2 mutation	TEAD inhibitor trials (IK-930, VT3989)
High TMB	Immunotherapy trials
CDKN2A deletion	CDK4/6 inhibitor trials

Treatment Selection

Finding	Treatment Implications
BAP1 loss	May respond to EZH2 inhibitors, PARP inhibitors
NF2/Hippo pathway	TEAD inhibitors in trials
High PD-L1	Better immunotherapy response
CDKN2A deletion	CDK4/6 inhibitors may help

Prognosis

Finding	Prognosis Implication
BAP1 loss	Generally better survival
CDKN2A homozygous deletion	Generally worse survival
Low tumor mutational burden	Less favorable for immunotherapy

Hereditary Mesothelioma Risk (BAP1 Tumor Predisposition Syndrome)

When Germline Testing Is Recommended

Consider germline testing if:

Tumor shows BAP1 loss
Diagnosed before age 50
Family history of mesothelioma
Multiple cancers in patient or family
Family history of uveal melanoma, kidney cancer, or other BAP1-associated tumors

What Inherited BAP1 Mutations Mean

BAP1 Tumor Predisposition Syndrome increases risk of:

Mesothelioma (both pleural and peritoneal)
Uveal melanoma (eye cancer)
Cutaneous melanoma
Renal cell carcinoma (kidney cancer)
Other cancers

Family Implications

If you have an inherited BAP1 mutation, your children and siblings have a 50% chance of carrying the same mutation. Genetic counseling can help families understand screening options.

Recommended Surveillance for BAP1 Carriers

Cancer Type	Screening	Frequency
Melanoma	Full body skin exam	Annual
Uveal melanoma	Dilated eye exam	Annual
Kidney cancer	Abdominal MRI or ultrasound	Annual or biennial
Mesothelioma	Consider chest imaging	As recommended

Getting Genetic Testing

Step 1: Talk to Your Oncologist

Ask about:

What testing is appropriate for your situation
Whether tumor tissue is available
If germline testing is recommended

Step 2: Tissue Requirements

Test Type	Sample Needed
NGS	Tumor tissue (biopsy or surgical specimen)
FISH	Tumor tissue
IHC	Tumor tissue
Germline	Blood or saliva
Liquid biopsy	Blood

Step 3: Processing and Results

NGS: 2-3 weeks
FISH: 3-5 days
IHC: 2-3 days
Germline: 2-4 weeks

Step 4: Results Review

Your oncologist or genetic counselor will explain:

What mutations were found
How results affect treatment options
Whether additional testing is needed
If family members should be tested

Should everyone with mesothelioma get genetic testing?▼

Comprehensive tumor genetic testing is increasingly recommended for all people with mesothelioma to identify treatment options and trial eligibility. Germline testing is specifically recommended for those with BAP1 loss, young age at diagnosis, or family history.

Will insurance cover genetic testing?▼

Most insurance plans cover tumor genetic testing when results may guide treatment. Commercial labs often have financial assistance programs. Ask about coverage before testing.

What is the difference between tumor testing and germline testing?▼

Tumor testing analyzes mutations in cancer cells. Germline testing analyzes inherited DNA. Tumor mutations are not passed to children, while germline mutations can be inherited.

If I have a BAP1 mutation, should my family be tested?▼

If germline testing confirms an inherited BAP1 mutation, first-degree relatives (parents, siblings, children) should be offered testing. A genetic counselor can help coordinate family testing.

How do genetic results affect treatment decisions?▼

Results can identify patients who may benefit from specific treatments (like TEAD inhibitors for NF2 mutations) or who qualify for clinical trials. They also help predict which treatments are most likely to work.

References

Genes, Chromosomes and Cancer. (2020). BAP1 tumor predisposition syndrome and associated tumors.
https://pubmed.ncbi.nlm.nih.gov/32237172/

Journal of Thoracic Oncology. (2022). The role of BAP1 in mesothelioma.
https://pubmed.ncbi.nlm.nih.gov/34979281/

Modern Pathology. (2020). CDKN2A deletion as a diagnostic marker for mesothelioma.
https://pubmed.ncbi.nlm.nih.gov/31591467/

Nature Communications. (2021). Comprehensive genomic profiling of malignant mesothelioma.
https://pubmed.ncbi.nlm.nih.gov/34907163/

Journal of Clinical Oncology. (2022). Guidelines for genetic testing in mesothelioma.
https://pubmed.ncbi.nlm.nih.gov/35377771/